Abstract
Solid tumors including glioblastoma have several characteristics that make them suitable targets for gene therapy. They are localized and thus accessible by direct intratumoral injection. In addition, metastases of these tumors are of late-stage occurrence. Therefore, early loco-regional control of the disease is paramount. Cancer gene therapies that utilize either adeno-associated virus (AAV) or adenovirus (Adv) gene delivery strategy have been developed. However, due to the low in vivo transduction efficiency of AAV and the undesirably strong immunogenecity of Adv, their utilization in clinical settings has been greatly limited.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
